Literature DB >> 7105628

Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis.

S H Dromgoole, D E Furst, R K Desiraju, R K Nayak, M A Kirschenbaum, H E Paulus.   

Abstract

Tolmetin kinetics were determined in the plasma and synovial fluid of five rheumatoid arthritis patients after they had ingested tolmetin (400 mg every 6 hr) for 7 days. Tolmetin was rapidly absorbed, with average peak levels in plasma and synovial fluid occurring at 45 min and 2 hr. The drug concentration in synovial fluid was higher than that in plasma for prolonged periods, while the rates of elimination from both plasma and synovial fluid were similar. The average half-lives of tolmetin in plasma and synovial fluid were 6.77 +/- 1.47 hr and 6.90 +/- 2.3 hr. Total prostaglandin E levels in synovial fluid of these patients were suppressed for at least 24 hr after the last dose of tolmetin, suggesting that PGE synthesis continues to be suppressed even by the very low concentrations of tolmetin remaining after 24 hr.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105628     DOI: 10.1038/clpt.1982.174

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.

Authors:  R O Day; A J McLachlan; G G Graham; K M Williams
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

Review 3.  A comparison of synovial fluid concentrations of non-steroidal anti-inflammatory drugs with their in vitro activity.

Authors:  E Urquhart
Journal:  Agents Actions       Date:  1991-03

4.  Variations in response to non-steroidal anti-inflammatory drugs.

Authors:  R O Day; P M Brooks
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

5.  Plasma and synovial fluid meclofenamic acid concentrations in patients with rheumatoid arthritis of the knee.

Authors:  J R Koup; D Thomas; E Tucker; A Black; M Ruderman; J A Dixon; A Kinkel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach.

Authors:  F J Flores-Murrieta; H C Ko; D M Flores-Acevedo; F J López-Muñoz; W J Jusko; M E Sale; G Castañeda-Hernández
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

7.  Pharmacokinetics of lumiracoxib in plasma and synovial fluid.

Authors:  Graham Scott; Christiane Rordorf; Christine Reynolds; Jyoti Kalbag; Michael Looby; Slavica Milosavljev; Margaret Weaver; John P Huff; Dennis A Ruff
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis.

Authors:  L Aarons; R Salisbury; M Alam-Siddiqi; L Taylor; D M Grennan
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

9.  Effect of 6-Methoxy-2-Naphthylacetic Acid (6MNA), the Active Metabolite of Nabumetone, on the Glycosaminoglycan Synthesis of Canine Articular Cartilage In Vitro : Comparison with Other Nonsteroidal Anti-Inflammatory Drugs.

Authors:  C Gentry; P Blower; R Spangler
Journal:  Clin Drug Investig       Date:  1995-12       Impact factor: 2.859

10.  In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis.

Authors:  Athina Theodoridou; Helen Gika; Eudoxia Diza; Alexandros Garyfallos; Loucas Settas
Journal:  Mediterr J Rheumatol       Date:  2017-03-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.